Becton, Dickinson and Company
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas E. Polen Jr.
- Full Time Employees
- 70,000
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1 Becton Drive Franklin Lakes NJ United States of America 07417-1880
- IPO Date
- Feb 21, 1973
- CIK
- 0000010795
- Website
- bd.com
- Similar Companies
- Business
- Becton, Dickinson and Company (BDX) manufactures and distributes medical devices, instrument systems, and reagents worldwide. The company develops, produces, and sells a broad portfolio of products including syringes, catheters, infusion therapy devices, and diagnostic systems; safety-engineered sharps and vascular access products; BD Alaris infusion pumps and Pyxis medication management solutions; BD FACSAria flow cytometers and Rhapsody single-cell analysis platforms; and laboratory automation systems such as BD Kiestra and BD Synapsys informatics. BD operates in three main segments—BD Medical, BD Life Sciences, and BD Interventional—serving healthcare facilities, laboratories, pharmaceutical companies, and research institutions across North America, Europe, Asia-Pacific, and emerging markets. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD maintains a global presence with manufacturing facilities in more than 50 countries. In recent developments, BD completed the spin-off of its Biosciences solution business into a standalone entity in early 2025, enabling focused growth in high-margin diagnostics and cell analysis; the company also expanded its partnership with GE HealthCare for integrated medication management technologies and launched new Alaris iPC infusion pump features to enhance cybersecurity and interoperability.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Jim Cramer: Buy Becton Dickinson, This Tech Stock Has Too High Valuation
Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
Peter Menziuso Named EVP and President, BD Interventional
AI, Robotics Key to Transforming Health Care: BD CEO
Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Is Becton Dickinson & Co (BDX) a Bargain After 4.2% Drop? GF Value Says Undervalued
Becton, Dickinson and Company Q2 Earnings Call Highlights
Is the Options Market Predicting a Spike in Becton Dickinson Stock?
BD Stock Up in Pre-Market Post Q2 Earnings & Revenue Beat, Margins Up
Becton, Dickinson and Company (BDX) Q2 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Becton Dickinson (BDX) Q2 Earnings
Becton Dickinson (BDX) Q2 Earnings and Revenues Surpass Estimates
Becton Dickinson raises annual profit forecast on strength in drug delivery devices
BD Appoints Vitor Roque Chief Financial Officer
BD Reports Second Quarter Fiscal 2026 Financial Results
Seeking Clues to Becton Dickinson (BDX) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
BD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI